Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01568762 · ClinicalTrials.gov registry record · Phase 1
To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01568762 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT01568762, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study is designed to compare the safety, tolerability, and pharmacokinetics of QBX258 (sequential administration of a fixed dose of VAK694 and single ascending doses of QAX576) in patients with well-controlled mild to moderate asthma.
Interventions
- DRUG QAX576 placebo
- DRUG QAX576
- DRUG VAK694
- DRUG VAK694 placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01568762
The ClinicalTrials.gov registry entry for NCT01568762 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which QAX576 placebo is the first listed.
NCT01568762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01568762 about?
NCT01568762 is a clinical study titled "To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma". This study is designed to compare the safety, tolerability, and pharmacokinetics of QBX258 (sequential administration of a fixed dose of VAK694 and single ascending doses of QAX576) in patients with well-controlled mild to moderate asthma.
What is the current status of trial NCT01568762?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2010-10.
What interventions are being tested in trial NCT01568762?
The interventions under investigation include: QAX576 placebo (DRUG), QAX576 (DRUG), VAK694 (DRUG), VAK694 placebo (DRUG).
Who is sponsoring clinical trial NCT01568762?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.